

Molbio Diagnostics makes \$30 M investment in OptraSCAN to advance digital pathology

15 November 2024 | News

OptraSCAN to expand its product portfolio and increase the availability of life-saving diagnostic technology to the remotest areas of India



Molbio Diagnostics, a molecular diagnostics solutions company, has announced its investment of \$30 million in OptraSCAN, a San Jose-based global diagnostics company.

This strategic partnership underscores Molbio's commitment to democratising healthcare by making advanced diagnostics accessible to underserved communities and healthcare providers worldwide. It enables OptraSCAN to accelerate the development and accessibility of digital pathology solutions powered by artificial intelligence. These solutions, which include cloud-based systems for slide scanning, image analysis, and secure data storage, aim to facilitate faster, more accurate diagnoses.

This initiative aligns with Molbio's goal of providing advanced diagnostics to every healthcare provider, regardless of location or resource limitations.

OptraSCAN's solutions are designed for various healthcare environments, from small laboratories to large medical facilities. With this partnership, OptraSCAN can expand its product portfolio and increase availability, making life-saving diagnostic technology accessible to facilities in rural and under-resourced regions in India.

In addition to improved access to diagnostic tools, this collaboration will support AI-driven pathology solutions that aim to empower healthcare professionals to diagnose diseases more efficiently, leading to better patient outcomes. The strategic investment will further OptraSCAN's research and development, strengthen its global presence, and bring quality diagnostics to regions historically lacking access to advanced healthcare technology.